Eikonoklastes Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Series B2

  • Latest Deal Amount
  • $16.1M

  • Investors
  • 4

Eikonoklastes Therapeutics General Information

Description

Developer of disruptive therapies designed to assist in the treatment of solid tumors and other pathologic conditions. The company's immunotherapies target the cell-surface receptor by utilizing a recombinant fusion protein, enabling healthcare professionals to treat triple-negative breast cancer, ovarian cancer, metastatic melanoma, and a broad range of other solid tumors.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2356 Park Avenue
  • Unit 17
  • Cincinnati, OH 45206
  • United States
+1 (513)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 2356 Park Avenue
  • Unit 17
  • Cincinnati, OH 45206
  • United States
+1 (513)

Eikonoklastes Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Eikonoklastes Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series B2) 05-Oct-2026 $16.1M Completed Pre-Clinical Trials
3. Later Stage VC (Series B1) 25-Jun-2024 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 06-May-2021 $3.18M $4.28M Completed Pre-Clinical Trials
1. Seed Round 04-Mar-2020 $1.1M $1.1M Completed Pre-Clinical Trials
To view Eikonoklastes Therapeutics’s complete valuation and funding history, request access »

Eikonoklastes Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B-2
Series B-1
Series A 3,890,977 $0.000010 $1.34 $1.34 1x $1.34 13.28%
Seed 3,228,567 $0.000010 $0.7 $0.7 1x $0.7 11.02%
To view Eikonoklastes Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Eikonoklastes Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of disruptive therapies designed to assist in the treatment of solid tumors and other pathologic conditions. T
Drug Discovery
Cincinnati, OH
8 As of 2026

South San Francisco, CA
 

Redwood City, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Eikonoklastes Therapeutics Competitors (3)

One of Eikonoklastes Therapeutics’s 3 competitors is CytomX Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Bolt Biotherapeutics Formerly VC-backed Redwood City, CA
Immunicom Venture Capital-Backed San Diego, CA
You’re viewing 3 of 3 competitors. Get the full list »

Eikonoklastes Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eikonoklastes Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Elkstone Family Office Minority
JobsOhio Ventures Venture Capital Minority
CincyTech Venture Capital Minority
R1 Capital (Columbus) Venture Capital Minority
To view Eikonoklastes Therapeutics’s complete investors history, request access »

Eikonoklastes Therapeutics FAQs

  • When was Eikonoklastes Therapeutics founded?

    Eikonoklastes Therapeutics was founded in 2019.

  • Where is Eikonoklastes Therapeutics headquartered?

    Eikonoklastes Therapeutics is headquartered in Cincinnati, OH.

  • What is the size of Eikonoklastes Therapeutics?

    Eikonoklastes Therapeutics has 8 total employees.

  • What industry is Eikonoklastes Therapeutics in?

    Eikonoklastes Therapeutics’s primary industry is Drug Discovery.

  • Is Eikonoklastes Therapeutics a private or public company?

    Eikonoklastes Therapeutics is a Private company.

  • What is the current valuation of Eikonoklastes Therapeutics?

    The current valuation of Eikonoklastes Therapeutics is .

  • What is Eikonoklastes Therapeutics’s current revenue?

    The current revenue for Eikonoklastes Therapeutics is .

  • How much funding has Eikonoklastes Therapeutics raised over time?

    Eikonoklastes Therapeutics has raised $27.5M.

  • Who are Eikonoklastes Therapeutics’s investors?

    Elkstone, JobsOhio Ventures, CincyTech, and R1 Capital (Columbus) have invested in Eikonoklastes Therapeutics.

  • Who are Eikonoklastes Therapeutics’s competitors?

    CytomX Therapeutics, Bolt Biotherapeutics, and Immunicom are competitors of Eikonoklastes Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process